-$0.28 Earnings Per Share Expected for Adaptimmune Therapeutics plc (NASDAQ:ADAP) This Quarter

Wall Street analysts expect that Adaptimmune Therapeutics plc (NASDAQ:ADAPGet Rating) will report earnings of ($0.28) per share for the current quarter, according to Zacks. Two analysts have provided estimates for Adaptimmune Therapeutics’ earnings. The lowest EPS estimate is ($0.32) and the highest is ($0.21). Adaptimmune Therapeutics reported earnings of ($0.24) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 16.7%. The business is scheduled to announce its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Adaptimmune Therapeutics will report full-year earnings of ($1.18) per share for the current financial year, with EPS estimates ranging from ($1.33) to ($0.99). For the next financial year, analysts expect that the firm will post earnings of ($0.86) per share, with EPS estimates ranging from ($1.42) to ($0.55). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that follow Adaptimmune Therapeutics.

Adaptimmune Therapeutics (NASDAQ:ADAPGet Rating) last announced its quarterly earnings results on Monday, May 9th. The biotechnology company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.04). Adaptimmune Therapeutics had a negative net margin of 1,836.31% and a negative return on equity of 76.84%. During the same period last year, the business posted ($0.24) earnings per share.

A number of equities analysts have commented on the company. SVB Leerink reduced their price objective on Adaptimmune Therapeutics from $7.00 to $3.00 and set a “market perform” rating on the stock in a research note on Tuesday, March 15th. StockNews.com initiated coverage on Adaptimmune Therapeutics in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. Finally, Zacks Investment Research raised Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, May 16th. Five analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $7.50.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ADAP. US Bancorp DE increased its holdings in Adaptimmune Therapeutics by 403.0% in the third quarter. US Bancorp DE now owns 5,729 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 4,590 shares during the last quarter. Levy Wealth Management Group LLC bought a new stake in Adaptimmune Therapeutics in the first quarter valued at about $36,000. Chicago Partners Investment Group LLC bought a new stake in Adaptimmune Therapeutics in the fourth quarter valued at about $38,000. Hunter Associates Investment Management LLC bought a new stake in shares of Adaptimmune Therapeutics in the fourth quarter worth about $41,000. Finally, Virtu Financial LLC bought a new stake in shares of Adaptimmune Therapeutics in the first quarter worth about $50,000.

Adaptimmune Therapeutics stock opened at $1.43 on Friday. The firm has a market cap of $231.69 million, a P/E ratio of -1.32 and a beta of 2.08. The business’s fifty day moving average is $1.78 and its two-hundred day moving average is $2.69. Adaptimmune Therapeutics has a 52 week low of $1.26 and a 52 week high of $6.86.

Adaptimmune Therapeutics Company Profile (Get Rating)

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets.

See Also

Get a free copy of the Zacks research report on Adaptimmune Therapeutics (ADAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Want More Great Investing Ideas?

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.